Search results
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 4 days agoBut what does June bring? Three Motley Fool contributors think the new month should usher in great investing opportunities. Here's why they picked AbbVie...
New antibiotic based on AstraZeneca drugs kills off deadly bacteria, spares the good guys
FierceBiotech· 6 days agoA new antibiotic based on drugs developed by AstraZeneca can kill off dangerous bacteria that cause...
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
The Wall Street Journal· 4 days agoMore patients can fend off the disease for months or years with targeted or immune-boosting drugs,...
AstraZeneca’s breast cancer trial shows ‘unprecedented’ results | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 4 days agoAstraZeneca and Daiichi Sankyo’s Enhertu slows the progression of breast cancer by about five months...
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 4 days agoStudy participants had already received one hormone therapy and a type of drug called a CDK 4/6...
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support...
Morningstar· 5 days agoTempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...
Patient’s Dark Fantasy About Aetna Lands Him in Jail
The Daily Beast via Yahoo News· 2 days agoMany Americans loathe their health insurance providers.A majority say they have severe concerns about financial hardship due to medical bills—even with...
Cancer Drugs: Deals and Licensing for Antibody-Drug Conjugates
The National Law Review· 13 hours agoAntibody-drug conjugates (ADCs) are a promising class of cancer treatments with an accelerating...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 3 days agoWe covered in detail results from a few of the most significant, including for AstraZeneca and...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 3 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...